查詢結果分析
相關文獻
- Sinonasal Diffuse Large B Cell Lymphoma
- Diffuse Large B-Cell Lymphoma of the Nipple
- Extranodal Diffuse Large B-Cell Lymphoma Presenting as Ileocolic Intussusception in Adolescent
- Bilateral Orbital Diffuse Large B-Cell Lymphoma--A Case Report
- 腿型瀰漫性大B細胞淋巴瘤:病例報告
- 鼻腔原發瀰漫性大B細胞淋巴瘤
- Hemophagocytic Syndrome Associated with Diffuse Large B-Cell Lymphoma: A Case Report
- 晚期瀰漫性大B細胞淋巴瘤之治療
- 胃淋巴癌的中西醫理與治療的整合思維
- Incidental Oral Artifact Detected by PET/CT Scans Mimicking Local Recurrence in Patients Treated with Chemotherapy for DLBCL
頁籤選單縮合
題 名 | 晚期瀰漫性大B細胞淋巴瘤之治療=Advanced Diffuse Large B Cell Lymphoma Treatment |
---|---|
作 者 | 鄭吉元; 陳宜正; 蔡慈貞; 張鴻; | 書刊名 | 藥學雜誌 |
卷 期 | 34:3=136 2018.09[民107.09] |
頁 次 | 頁24-30 |
分類號 | 415.6 |
關鍵詞 | 瀰漫性大B細胞淋巴瘤; Diffuse large B-cell lymphoma; DLBCL; |
語 文 | 中文(Chinese) |
中文摘要 | 瀰漫性大B細胞淋巴瘤 (diffuse large B-cell lymphoma,DLBCL) 是屬於侵襲性B 細胞非何杰金氏淋巴瘤 (non-Hodgkin lymphoma,NHL),在臺灣地區佔 NHL 的50- 60%。晚期 DLBCL (Ann Arbor 第三或第四期) 佔所有 DLBCL 病人的60-70%。R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone) 是晚期 DLBCL 的第一 線標準治療,約有一半的病人可治癒;但仍有將近三分之一的患者,使用 R-CHOP 無 效或是之後疾病復發。對於復發或頑固性 DLBCL 的治療,應優先考慮進行自體幹細 胞移植 (autologous stem cell transplantation,ASCT)。試驗中的新興藥物,大致上可分 為免疫治療藥物和小分子標靶藥物。針對 DLBCL 不同的基因表現譜 (gene expression profiling,GEP) 給予最適當的藥物組合是未來發展的方向。 |
英文摘要 | Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma (NHL) of B cells, accounting for 50-60% of NHL in Taiwan. Advanced DLBCL (Ann Arbor stage III or IV) comprises 60-70% of the total DLBCL patients. R-CHOP (rituximab/ cyclophosphamide/doxorubicin/vincristine/prednisolone) is the standard first-line treatment of advanced DLBCL and about half of the patients can be cured with this regimen. Despite R-CHOP treatment, up to one-third of patients fail or relapse after first-line treatment. Autologous stem cell transplantation (ASCT) should be a priority for patients with relapsed or refractory DLBCL. Emerging drugs in the clinical trials for DLBCL are classified into immuno-based drugs and small molecular targeted drugs. The optimal drug combination based on gene expression profiling is the future direction of development for the treatment of advanced DLBCL. |
本系統中英文摘要資訊取自各篇刊載內容。